Name: | Description: | Size: | Format: | |
---|---|---|---|---|
3.31 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Introduction: The management of Sickle cell disease (SCD) in sub-Saharan Africa (SSA) suffers from the lack of universal infant and population screening, inadequate access to standard treatment, and poor public health prioritization amidst unstable political systems. Areas covered: The state of evidence-based management of SCD in SSA was investigated, including the sustainability of international funding agencies. Expert opinion: Current efforts are fragmentary along language lines; sometimes driven by the funder's objectives and not the national agenda. The review highlighted the role of internal and external partnerships, such as SPARCO, ARISE, and CONSA, as well as technology-based support for the implementation of evidence-based care for SCD. We advocate for increased funding to implement SCD comprehensive care in line with the WHO SCD Framework for Primary, Secondary, Tertiary, and Specialist Comprehensive Care at the state and national level. To achieve this objective, it is important that SCD, as a leading non-communicable disease in Africa, be mandated as a standing agenda for the National Council of Ministers at the African Union, the WHO, and other regional bodies in Africa.
Description
We acknowledge the WHO permission for figure usage in the paper. Authors acknowledge the benefit of the ARISE project, which received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 824021.
Keywords
Sickle cell disease Sub-Saharan Africa Anemia Antimalarial prophylaxis Blood transfusion Genetic counseling Health financing Hydroxyurea Malaria prophylaxis Newborn screening Penicillin V
Citation
Brito M, Ginete C, Ofakunrin A, Diaku-Akinwumi I, Inusa BP. Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management. Expert Rev Hematol. 2025;18(6):447-62.
Publisher
Taylor and Francis